EGFR and non-small cell lung carcinoma: First-generation TKIs, such as gefitinib, which targets L858R and exon 19 deletion mutants of EGFR by reversibly competing with ATP, have been considered the first-line therapy for NSCLC patients with EGFR mutations [19].